PHARMACOTHERAPEUTICS FOR ADVANCED PRACTICE NURSE PRESCRIBERS

PHARMACOTHERAPEUTICSbFORbADVANCEDbPRACTICEbNURSEbPRESCRIBERS,QUESTI
ONSb&bANSWERSbFULLYbANALYSEDbEDITIONbEXAMb100%bCORRECTLY/VERIFIEDbANS
WERSbWITHbSATISFACTIONbGUARANTEEDbSUCCESSbLATESTbUPDATEb2023b5THbEDITI
ONbWOObROBINSONbTESTbBANKbGRADEDbA+

Chapter 1. b b




An Introduction to Pharmacogenetics
b b b




Multiple Choice b



Identify the choice that best completes the statement or answers the question.
b b b b b b b b b b b




b 1. Genetic polymorphisms account for differences in metabolism, including:
bbbb b b b b b b b b



1. Poor metabolizers, who lack a working enzyme
b b b b b b



2. Intermediate metabolizers, who have one working, wild-type allele and one mutant
b b b b b b b b b b



3. Extensive metabolizers, with two normally functioning alleles
b b b b b b



4. All of the above
b b b




b 2. Up to 21% of Asians are ultra-rapid 2D6 metabolizers, leading to:
bbbb b b b b b b b b b b b



1. A need to monitor drugs metabolized by 2D6 for toxicity
b b b b b b b b b



2. Increased dosages needed of drugs metabolized by 2D6, such as the s
b b b b b b b b b b b



elective serotoreuptake inhibitors
b b b



3. Decreased conversion of codeine to morphine by CYP 2D6
b b b b b b b b



4. The need for lowered dosages of drugs, such as beta blockers
b b b b b b b b b b




b 3. Rifampin is a nonspecific CYP450 inducer that may:
bbbb b b b b b b b b



1. Lead to toxic levels of rifampin and must be monitored closely
b b b b b b b b b b



2. Cause toxic levels of drugs, such as oral contraceptives, when coadministered
b b b b b b b b b b



3. Induce the metabolism of drugs, such as oral contraceptives, leading to therapeutic
b b b b b b b b b b b




PHARMACOTHERAPEUTICSbFORbADVANCEDbPRACTICEbNURSEbPRESCRIBERS,QUESTI
ONSb&bANSWERSbFULLYbANALYSEDbEDITIONbEXAMb100%bCORRECTLY/VERIFIEDbANS
WERSbWITHbSATISFACTIONbGUARANTEEDbSUCCESSbLATESTbUPDATEb2023b5THbEDITI
ONbWOObROBINSONbTESTbBANKbGRADEDbA+

, PHARMACOTHERAPEUTICSbFORbADVANCEDbPRACTICEbNURSEbPRESCRIBERS,QUESTI
ONSb&bANSWERSbFULLYbANALYSEDbEDITIONbEXAMb100%bCORRECTLY/VERIFIEDbANS
WERSbWITHbSATISFACTIONbGUARANTEEDbSUCCESSbLATESTbUPDATEb2023b5THbEDITI
ONbWOObROBINSONbTESTbBANKbGRADEDbA+

4. Cause nonspecific changes in drug metabolism
b b b b b




b 4. Inhibition of P-glycoprotein by a drug such as quinidine may lead to:
bbbb b b b b b b b b b b b b



1. Decreased therapeutic levels of quinidine
b b b b



2. Increased therapeutic levels of quinidine
b b b b



3. Decreased levels of a coadministered drug, such as digoxin, that req
b b b b b b b b b b



uires P-glycoprabsorption and elimination
b b b b



4. Increased levels of a coadministered drug, such as digoxin, that requ
b b b b b b b b b b



ires P-glycoproabsorption and elimination
b b b b




b 5. Warfarin resistance may be seen in patients with VCORC1 mutation, leading to:
bbbb b b b b b b b b b b b b



1. Toxic levels of warfarin building up
b b b b b



2. Decreased response to warfarin b b b



3. Increased risk for significant drug interactions with warfarin
b b b b b b b



4. Less risk of drug interactions with warfarin
b b b b b b




b


bbbb6. Genetic testing for VCORC1 mutation to assess potential warfar
b b b b b b b b b



in resistance is requiredprior to prescribing warfarin.
b b b b b b b



1. True
2. False
b


bbbb7. Pharmacogenetic testing is required by the U.S. Food and Drug
b b b b b b b b b b b



Administration prior toprescribing: b b b



1. Erythromycin

PHARMACOTHERAPEUTICSbFORbADVANCEDbPRACTICEbNURSEbPRESCRIBERS,QUESTI
ONSb&bANSWERSbFULLYbANALYSEDbEDITIONbEXAMb100%bCORRECTLY/VERIFIEDbANS
WERSbWITHbSATISFACTIONbGUARANTEEDbSUCCESSbLATESTbUPDATEb2023b5THbEDITI
ONbWOObROBINSONbTESTbBANKbGRADEDbA+

,PHARMACOTHERAPEUTICSbFORbADVANCEDbPRACTICEbNURSEbPRESCRIBERS,QUESTI
ONSb&bANSWERSbFULLYbANALYSEDbEDITIONbEXAMb100%bCORRECTLY/VERIFIEDbANS
WERSbWITHbSATISFACTIONbGUARANTEEDbSUCCESSbLATESTbUPDATEb2023b5THbEDITI
ONbWOObROBINSONbTESTbBANKbGRADEDbA+

2. Digoxin
3. Cetuximab




PHARMACOTHERAPEUTICSbFORbADVANCEDbPRACTICEbNURSEbPRESCRIBERS,QUESTI
ONSb&bANSWERSbFULLYbANALYSEDbEDITIONbEXAMb100%bCORRECTLY/VERIFIEDbANS
WERSbWITHbSATISFACTIONbGUARANTEEDbSUCCESSbLATESTbUPDATEb2023b5THbEDITI
ONbWOObROBINSONbTESTbBANKbGRADEDbA+

, PHARMACOTHERAPEUTICSbFORbADVANCEDbPRACTICEbNURSEbPRESCRIBERS,QUESTI
ONSb&bANSWERSbFULLYbANALYSEDbEDITIONbEXAMb100%bCORRECTLY/VERIFIEDbANS
WERSbWITHbSATISFACTIONbGUARANTEEDbSUCCESSbLATESTbUPDATEb2023b5THbEDITI
ONbWOObROBINSONbTESTbBANKbGRADEDbA+

4. Rifampin
b


8. Carbamazepine has a Black Box Warning recommending testing fo
bbbb b b b b b b b b b



r the HLA-
b b



B*1502 allelein patients with Asian ancestry prior to starting therapy due
b b b b b b b b b b b



to:
b



1. Decreased effectiveness of carbamazepine in treating seizures in Asian patients wit
b b b b b b b b b b



HLA-B*1502 allele b



2. Increased risk for drug interactions in Asian patients with the HLA-B*1502 allele
b b b b b b b b b b b



3. Increased risk for Stevens-Johnson syndrome in Asian patients with HLA-B*1502 a
b b b b b b b b b b



4. Patients who have the HLA-
b b b b



B*1502 allele being more likely to have a resistance tocarbamazepi
b b b b b b b b b b



ne
b


9. A genetic variation in how the metabolite of the cancer dru
bbbb b b b b b b b b b b b



g irinotecan SN-38 isinactivated by the body may lead to:
b b b b b b b b b b



1. Decreased effectiveness of irinotecan in the treatment of cancer
b b b b b b b b



2. Increased adverse drug reactions, such as neutropenia
b b b b b b



3. Delayed metabolism of the prodrug irinotecan into the active metabolite SN-38
b b b b b b b b b b



4. Increased concerns for irinotecan being carcinogenic
b b b b b




b 10. Patients who have a poor metabolism phenotype will have:
bb b b b b b b b b b



1. Slowed metabolism of a prodrug into an active drug, leading to accumulation of pr
b b b b b b b b b b b b b




PHARMACOTHERAPEUTICSbFORbADVANCEDbPRACTICEbNURSEbPRESCRIBERS,QUESTI
ONSb&bANSWERSbFULLYbANALYSEDbEDITIONbEXAMb100%bCORRECTLY/VERIFIEDbANS
WERSbWITHbSATISFACTIONbGUARANTEEDbSUCCESSbLATESTbUPDATEb2023b5THbEDITI
ONbWOObROBINSONbTESTbBANKbGRADEDbA+